CLYM:NASDAQ, Climb Bio, Inc.
CLYM stock overview
Climb Bio, Inc. (CLYM:NASDAQ) closed at $9.28 on November 19, 2026,
down 0.22% on the day.
The stock trades 49.4% below its 52-week high of $18.33
and 467.6% above its 52-week low of $1.64.
Over the past year, it gained 445.9%.
Climb Bio, Inc. is part of the Health Care sector.
Key figures
- Price
- $9.28
- Day change
- -0.22%
- Volume
- 586,596
- Average volume
- 1,383,237
- Market cap
- 545M+
- 52-week range
- $1.64 – $18.33
- 50-day average
- $11.23
- 200-day average
- $10.74
Price action over the past year
In 252 trading sessions since November 19, 2025, CLYM closed higher on 131 days (52%).
Its best day was December 12, 2025 (+30.43%) and its worst was October 26, 2026 (-13.54%).
The stock moved 10% or more in a single session 21 times.
Recent signals
CLYM news
-
Nov 6, 2026:
Wedbush keeps Climb Bio on Best Ideas List, raises price target
-
Nov 5, 2026:
Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
-
Nov 4, 2026:
Wedbush Says This Stock Remains a Top Pick Despite Recent Volatility
-
Nov 4, 2026:
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
-
Nov 2, 2026:
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
-
Oct 24, 2026:
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
-
Oct 23, 2026:
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
-
Oct 20, 2026:
Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline
About Climb Bio, Inc.
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
Similar stocks
Find more stocks like CLYM with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.